The reference genome is the backbone of all read-mapping analyses in genomics. When sequencing machines produce millions of short DNA fragments, bioinformaticians align those fragments to a reference assembly to determine where each fragment originated. Any sequence absent from the reference cannot be confidently assigned, and reads derived from such regions are typically discarded or misaligned. The most widely used reference, GRCh38, still contains large gaps, particularly in centromeres, pericentromeric satellite arrays, acrocentric chromosome short arms, and other tandemly repeated regions that were technically impossible to resolve with earlier sequencing technologies. The T2T consortium’s complete assembly, designated hs1, closed essentially all of these gaps by combining long-read and ultra-long-read sequencing with advanced assembly algorithms, delivering the first gapless view of a human genome.

The Cologne team reasoned that this gapless reference could change the picture of HPV integration. Viruses are known to preferentially insert into regions of genomic fragility, and highly repetitive DNA is both structurally complex and prone to breakage. If integration events occur inside centromeric or pericentromeric satellites, analyses based on GRCh38 would systematically miss them, not because the events are rare but because the reference lacks the sequence needed to detect them. To test this hypothesis, the researchers reanalyzed datasets from three independent studies that had originally characterized HPV integration using complementary sequencing platforms: short-read Illumina sequencing, PacBio continuous long reads (CLR), PacBio high-fidelity (HiFi) reads, and ultra-long Oxford Nanopore reads. This diversity of technologies allowed them to ask whether the new reference benefits every sequencing modality or only the newest long-read approaches.

The results were striking. Reanalysis against the T2T assembly confirmed the majority of integration breakpoints reported in the original studies, validating the overall reliability of prior work. But in addition to these confirmations, the team identified numerous previously undetected sites, raising the total number of detected breakpoints from 446 to 799. In other words, nearly 40 percent of the integration landscape had been missed by analyses relying on incomplete references. This is not a marginal technical correction; it represents a substantial revision of our understanding of where HPV DNA inserts itself in the cancer genome and how frequently it targets regions that were previously uncharted territory.

Perhaps the most important finding is where the newly discovered breakpoints reside. The additional integrations frequently localized to repeat-rich genomic regions, including centromeric and pericentromeric satellite sequences that were entirely absent from earlier reference assemblies. Centromeres are the structures that anchor chromosome segregation during cell division, and their disruption is a hallmark of chromosomal instability in cancer. Pericentromeric heterochromatin, meanwhile, plays roles in maintaining genome architecture and silencing repetitive elements. Viral integration into these regions could therefore contribute to carcinogenesis through mechanisms that have been almost entirely unexplored, such as compromising centromere function, altering satellite RNA biology, or promoting the formation of dicentric chromosomes and other structural aberrations.

A particularly consequential observation concerns sequencing technology. One might assume that only long-read platforms, with their ability to span repetitive DNA, could detect integrations in satellite regions. The study demonstrates otherwise: integration events within these repeat-rich regions were detectable not only in long-read datasets but also in short-read Illumina data, provided the reads were mapped against the complete T2T reference. The limiting factor was never the sequencing data itself; it was the reference against which the data were aligned. This means that the vast archives of short-read cancer sequencing data already deposited in public repositories contain a wealth of information about viral integration in repetitive DNA that has never been extracted. Reanalysis, rather than new data generation, may be sufficient to uncover clinically relevant events.

The methodological implications extend beyond HPV. Many viruses integrate into host genomes, including hepatitis B virus in hepatocellular carcinoma, HIV in infected T cells, and various oncogenic retroviruses. All integration studies that rely on read mapping share the same dependence on reference completeness. The Cologne findings suggest that any such study conducted against GRCh38 or earlier assemblies may have systematically underestimated integration events, particularly within structurally complex regions. The same logic applies to other rearrangement analyses, such as the detection of extrachromosomal circular DNA (ecDNA), which is increasingly recognized as a driver of oncogene amplification, and to the characterization of common fragile sites (CFSs), which are preferential targets of both viral integration and chromosome breakage.

For HPV research specifically, the expanded integration map opens several avenues of investigation. Previous work established that HPV integrations cluster near or within genes such as TP63, MYC, and E2F-family regulators, and that integration often preserves expression of the viral E6 and E7 oncogenes while disrupting the viral E2 gene that normally restrains them. Whether integrations in centromeric satellites exert oncogenic effects through chromosomal instability, epigenetic perturbation, or other routes remains to be determined. The study also raises questions about formalin-fixed paraffin-embedded (FFPE) clinical specimens, the standard material in pathology archives, whose degraded DNA may behave differently in T2T-based analyses. Tools developed for high-throughput viral integration detection, such as HIVID, will likely need recalibration against the complete reference to realize its full potential.

The authors emphasize that their findings demonstrate a systematic underestimation of HPV integration events caused by incomplete reference assemblies, and they advocate for adopting complete human genome references as the standard in viral integration analyses. Because the study is a brief report based on reanalysis of existing datasets, the biological consequences of the newly mapped integrations remain to be established experimentally, and the researchers are careful not to overstate functional claims. Nevertheless, the message for the field is clear and actionable: the data to find these events already exist, and the reference genome needed to find them is now available. As more laboratories adopt the T2T assembly, the integration landscapes of HPV-associated cancers, and of virus-associated cancers more broadly, are likely to be redrawn with a completeness that was unimaginable only a few years ago, potentially revealing new biomarkers and therapeutic targets hidden in the most repetitive corners of the human genome.

Subject of Research: Reanalysis of HPV genome integration breakpoints using the complete telomere-to-telomere human reference genome

Article Title: Revisiting HPV integration landscapes using telomere-to-telomere human genome reference closes the gaps in HPV integration sites search

Article References: Pacholewska, A., Khan, B. Y., & Schweiger, M. R. (2026). Revisiting HPV integration landscapes using telomere-to-telomere human genome reference closes the gaps in HPV integration sites search. Virology Journal, 23(1), Article 213. https://doi.org/10.1186/s12985-026-03241-y

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03241-y

Keywords: HPV, viral integration, telomere-to-telomere genome, T2T-CHM13, breakpoints, centromeres, satellite DNA, repetitive regions, cervical cancer, genome assembly, bioinformatics, carcinogenesis

Yet the numbers remain sobering. According to the review, even with the best currently available regimens, the functional cure rate among patients with chronic hepatitis B stays below 30 percent, and in many treatment settings it is far lower. Nucleos(t)ide analogues such as entecavir and tenofovir suppress viral replication with remarkable potency and an excellent safety profile, but they act on the reverse transcriptase step of the hepatitis B virus life cycle and leave the intracellular reservoirs of viral genetic material untouched. Pegylated interferon-alpha, the other pillar of standard therapy, can reinvigorate antiviral immune responses in a subset of patients, but response rates are limited and tolerability issues frequently force discontinuation. The result is a therapeutic plateau: viral suppression is easy to achieve, but genuine immune-mediated control of the infection remains the exception rather than the rule.

At the heart of this plateau, the authors identify the persistence of covalently closed circular DNA, or cccDNA, as the central virological obstacle. cccDNA is the circular, episodic form of the hepatitis B virus genome that resides in the nucleus of infected hepatocytes and serves as the transcriptional template for all viral RNAs, including the pregenomic RNA from which new viral particles are assembled. Because cccDNA is stable, long-lived and present in minute quantities per cell, it evades both the cytoplasmic degradation pathways triggered by nucleos(t)ide analogues and the surveillance of the immune system, which struggles to recognize infected hepatocytes that produce little or no viral antigen. Clearing cccDNA from the liver would require either eliminating every infected hepatocyte or inducing selective degradation of the minichromosome itself, and neither approach is currently achievable with acceptable safety in the overwhelming majority of patients.

Compounding the cccDNA problem is a second form of viral persistence that the review highlights in detail: the integration of hepatitis B virus DNA into the genome of the host hepatocyte. Integration occurs frequently during the chronic phase of infection, driven by the_error-prone nature of viral replication and the continual turnover of infected cells. Integrated viral sequences are typically rearranged and replication-defective, but they can act as persistent factories for hepatitis B surface antigen, sustaining high circulating levels of HBsAg even when cccDNA transcription has been effectively silenced. This has two major consequences. First, integrated DNA means that surface antigen loss cannot automatically be equated with the elimination of the viral reservoir, complicating the interpretation of treatment endpoints. Second, chromosomal integration is a recognized mutagenic event, and insertional disruption of host genes such as TERT has been implicated in the development of hepatocellular carcinoma, linking viral persistence directly to the most feared clinical outcome of chronic infection.

The review then turns to the immunological face of the problem, describing how prolonged exposure to elevated levels of viral antigens — above all hepatitis B surface antigen and hepatitis B e antigen — induces a state of immune tolerance that is sculpted from the very earliest stages of infection. In patients infected at birth or in early childhood, the developing immune system encounters enormous quantities of circulating antigen during the critical windows in which tolerance mechanisms are established. High antigen loads drive the deletion or functional silencing of HBV-specific T cells, promote the differentiation of regulatory T cells and exhaust antigen-presenting dendritic cells, so that by the time chronicity is established the immune system has been trained, in effect, to ignore the virus. Maternal antigen passage and the unique tolerogenic environment of the liver, which is continuously exposed to gut-derived material and normally biased toward immune non-responsiveness, reinforce this state and help explain why infection acquired early in life so rarely resolves spontaneously.

Even in patients whose T cells do persist, the review documents a landscape of immune exhaustion and dysfunction operating at multiple regulatory levels. HBV-specific CD8 T cells in chronic hepatitis B display the classic molecular signature of exhaustion: sustained expression of inhibitory receptors such as PD-1, CTLA-4, TIM-3 and LAG-3, shortened telomeres, impaired cytotoxic function and a shift toward a terminally differentiated, senescent phenotype. CD4 helper function is similarly compromised, weakening the support that CD8 cells require for sustained antiviral activity. Beyond the T cell compartment, natural killer cell function is dysregulated, B cell responses are blunted with defective production of neutralizing anti-HBs antibodies, and the intrahepatic cytokine milieu — enriched in suppressive mediators such as interleukin-10 and indoleamine 2,3-dioxygenase — actively restrains inflammatory responses. Exhausted T cells, the authors emphasize, are not simply passive casualties; they represent a partially reversible differentiation state, which is precisely why they have become the focal point of new immunotherapeutic strategies.

It is against this mechanistic backdrop that the review surveys the emerging arsenal of immunotherapy. Therapeutic vaccines aim to present HBV antigens in an immunogenic context that can break tolerance and prime new antiviral T cell responses. Checkpoint inhibitors, most notably antibodies directed against PD-1 or PD-L1, seek to reverse the exhausted state of HBV-specific T cells, an approach supported by incidental observations of HBsAg decline in cancer patients treated with such agents. Agonists of pattern-recognition receptors, including Toll-like receptor 7 and 8 agonists, are designed to reawaken innate antiviral defenses and restore interferon production within the liver. Additional strategies under investigation include engineered T cell technologies, cytokine modulation, and combinations that pair direct-acting antivirals with immune interventions to first reduce antigen load and then rebuild antiviral immunity. The authors stress, however, that no single agent has yet demonstrated the capacity to induce functional cure reliably, and that the field’s most promising direction lies in rational combination: reducing the antigenic burden, releasing the brakes on T cell function, and providing the innate cytokine signals needed to coordinate a durable multi-layered response.

The review also underscores why the liver’s unique immunobiology makes this task so difficult. The hepatic environment is constitutively tolerogenic, populated by liver sinusoidal endothelial cells, Kupffer cells and stellate cells that favor the induction of regulatory rather than effector T cell responses. Any curative strategy must therefore overcome not only the viral reservoirs and the exhaustion of the adaptive immune system, but also an organ-specific architecture that has evolved to suppress inflammation. Biomarker development is identified as an equally pressing need: quantitative HBsAg levels, hepatitis B RNA signatures and emerging measures of immune restoration are all being explored as tools to identify which patients are most likely to benefit from which combination, and to shorten the lengthy trials that current endpoints demand.

By synthesizing virological persistence mechanisms, the layered failure of antiviral immunity and the emerging immunotherapeutic toolkit into a single framework, Lin, Yu and Sun aim to provide both a theoretical foundation and practical critical perspective for the clinical translation of functional cure strategies. Their central message is one of mechanistic realism: the obstacles to curing chronic hepatitis B functionally are not a single barrier but an interlocking system of viral reservoirs, integrated DNA, antigen-driven tolerance and multi-level immune exhaustion. Understanding how these pieces reinforce one another — and designing combinations that dismantle them in the correct sequence — is, the authors conclude, the surest path toward turning a goal achieved by fewer than a third of patients today into a routine clinical outcome tomorrow.

Subject of Research: Immunological mechanisms and barriers to achieving a functional cure for chronic hepatitis B

Article Title: The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B

Article References: Lin, L., Yu, D., & Sun, S. (2026). The core obstacles and immunological mechanisms in the study of functional cure for Chronic Hepatitis B. Virology Journal. https://doi.org/10.1186/s12985-026-03310-2

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03310-2

Keywords: chronic hepatitis B, functional cure, HBV, cccDNA, HBsAg loss, immune exhaustion, viral integration, immunotherapy, T cell dysfunction, immune tolerance, liver disease, antiviral therapy